NanoBio and GSK sign licensing agreement for cold sore treatment

Published: 17-Dec-2009
Regulatory

Biopharmaceutical firm NanoBio Corporation of Ann Arbor, Michigan, US and drugmaker GlaxoSmithKline (GSK) have agreed an exclusive licensing deal in the US and Canada for the over-the-counter use of NB-001, a patented compound for the treatment of cold sores. Developed by NanoBio, NB-001 is said to be an effective treatment against the herpes labialis virus that causes cold sores.


Biopharmaceutical firm NanoBio Corporation of Ann Arbor, Michigan, US and drugmaker GlaxoSmithKline (GSK) have agreed an exclusive licensing deal in the US and Canada for the over-the-counter use of NB-001, a patented compound for the treatment of cold sores. Developed by NanoBio, NB-001 is said to be an effective treatment against the herpes labialis virus that causes cold sores.

NanoBio has completed two Phase 2 clinical trials of NB-001, demonstrating clear efficacy and a good safety profile in patients and plans to enter Phase 3 testing soon.

Under the terms of the agreement, NanoBio will receive an upfront payment of US$14.5m, and is eligible to receive milestones of up to US$40m plus single-digit royalties on future sales.

GSK already offers Abreva, which is said to be the leading cold sore treatment with a greater than 50% share. It is the only OTC medicine approved by the US Food & Drug Administration that is proven to shorten cold sore healing time.

"I am pleased to announce this partnership with GSK as it will enable the development and commercialisation of NB-001 to its fullest potential," said James Baker, NanoBio's ceo and founder.

"On a broader scale, this partnership further validates the promise of our proprietary platform technology, and its potential use in a wide range of dermatological and anti-infective applications."

Roger Scarlett-Smith, president, GSK Consumer Healthcare North America, said: "With Abreva, we have a very effective cold sore treatment in the category and look forward to building on that platform with this new technology from NanoBio."

  • Companies:
  • GlaxoSmithKline
See more

You may also like

Regulatory

GSK's respiratory syncytial virus vaccine receives approval

Read more
The MHRA has authorised has authorised Arexvy (respiratory syncytial virus vaccine, adjuvanted) for immunisation for LRTD in adults 60 years or older

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

GSK's respiratory syncytial virus vaccine receives approval

The MHRA has authorised has authorised Arexvy (respiratory syncytial virus vaccine, adjuvanted) for immunisation for LRTD in adults 60 years or older
Manufacturing

Tickets now on sale for 2023 Manufacturing Chemist Live

Super early bird tickets are now on sale for the annual conference due to take place in Birmingham on 24 – 25 May 2023
Ingredients

Therapeutic: daprodustat for anaemia

Chronic kidney disease (CKD) is a rising health burden, with risk factors including diabetes, hypertension, obesity and primary renal disorders
Regulatory

Pharma CEOs pledge to uphold scientific standards for COVID vaccine

The pledge outlines "a united commitment to uphold the integrity of the scientific process"
Ingredients

Therapeutics: anticancer agent

There has been a lot of interest in anti-programmed death ligand 1 (anti-PD-1) therapies to treat cancers. Another, dostarlimab, is under development at GlaxoSmithKline
Media

The pharma industry's response to PM’s latest Brexit speech

The Association of the British Pharmaceutical Industry (ABPI) – representing global pharmaceutical businesses in the UK including GSK, AstraZeneca, Pfizer and Roche – has responded to the ‘Road to Brexit’ speech by Prime Minister Theresa May
Regulatory

Breath Biopsy Platform integrated into GSK’s clinical trial

The phase II respiratory disease clinical trial will analyse breath biomarkers to improve understanding of the treatment effects of a novel GlaxoSmithKline (GSK) pipeline drug candidate for chronic obstructive pulmonary disease (COPD)
Subscribe now